| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Leanne M Williams, Carmel M Loughland, Melissa J Green, Anthony W F Harris, Evian Gordo. Emotion perception in schizophrenia: an eye movement study comparing the effectiveness of risperidone vs. haloperidol. Psychiatry research. vol 120. issue 1. 2004-03-08. PMID:14500110. |
emotion perception in schizophrenia: an eye movement study comparing the effectiveness of risperidone vs. haloperidol. |
2004-03-08 |
2023-08-12 |
human |
| Leanne M Williams, Carmel M Loughland, Melissa J Green, Anthony W F Harris, Evian Gordo. Emotion perception in schizophrenia: an eye movement study comparing the effectiveness of risperidone vs. haloperidol. Psychiatry research. vol 120. issue 1. 2004-03-08. PMID:14500110. |
we used a psychophysiological marker of visual attention (the visual scanpath) to investigate the effects of atypical (risperidone) vs. typical (haloperidol) antipsychotic medication on facial emotion perception in schizophrenia (n=28) and healthy control (n=28) groups. |
2004-03-08 |
2023-08-12 |
human |
| Leanne M Williams, Carmel M Loughland, Melissa J Green, Anthony W F Harris, Evian Gordo. Emotion perception in schizophrenia: an eye movement study comparing the effectiveness of risperidone vs. haloperidol. Psychiatry research. vol 120. issue 1. 2004-03-08. PMID:14500110. |
of the schizophrenia subjects, 15 were prescribed risperidone. |
2004-03-08 |
2023-08-12 |
human |
| Leanne M Williams, Carmel M Loughland, Melissa J Green, Anthony W F Harris, Evian Gordo. Emotion perception in schizophrenia: an eye movement study comparing the effectiveness of risperidone vs. haloperidol. Psychiatry research. vol 120. issue 1. 2004-03-08. PMID:14500110. |
these findings suggest that risperidone may play a specific role in schizophrenia in the ability to attend to salient features, and to integrate this information into an accurate percept for neutral and positive expressions in particular. |
2004-03-08 |
2023-08-12 |
human |
| Jan Volavka, Pal Czobor, Thomas B Cooper, Brian Sheitman, Jean-Pierre Lindenmayer, Leslie Citrome, Joseph P McEvoy, Jeffrey A Lieberma. Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. The Journal of clinical psychiatry. vol 65. issue 1. 2004-03-02. PMID:14744169. |
prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. |
2004-03-02 |
2023-08-12 |
Not clear |
| Herbert Y Meltzer, Zhu Li, Yasuhiro Kaneda, Junji Ichikaw. Serotonin receptors: their key role in drugs to treat schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. vol 27. issue 7. 2004-02-24. PMID:14642974. |
this hypothesis is consistent with the atypical features of quetiapine, olanzapine, risperidone, and ziprasidone, which are the most common treatments for schizophrenia in the united states and many other countries, as well as a large number of compounds in various stages of development. |
2004-02-24 |
2023-08-12 |
Not clear |
| Philip D Harvey, Michael F Green, Susan R McGurk, Herbert Y Meltze. Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study. Psychopharmacology. vol 169. issue 3-4. 2004-02-23. PMID:12590356. |
the effects of risperidone and olanzapine on cognitive functioning in patients with schizophrenia were compared in a randomized, double-blind trial. |
2004-02-23 |
2023-08-12 |
Not clear |
| Scot E Purdon, Neil Woodward, Stacy R Lindborg, Emmanuel Sti. Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol. Psychopharmacology. vol 169. issue 3-4. 2004-02-23. PMID:12827347. |
procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol. |
2004-02-23 |
2023-08-12 |
Not clear |
| Uriel Heresco-Levy, Marina Ermilov, Pesah Lichtenberg, Gali Bar, Daniel C Javit. High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biological psychiatry. vol 55. issue 2. 2004-02-23. PMID:14732596. |
high-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. |
2004-02-23 |
2023-08-12 |
Not clear |
| Frank-Gerald Pajon. Risperidone in acute and long-term therapy of schizophrenia--a clinical profile. Progress in neuro-psychopharmacology & biological psychiatry. vol 28. issue 1. 2004-02-18. PMID:14687852. |
risperidone in acute and long-term therapy of schizophrenia--a clinical profile. |
2004-02-18 |
2023-08-12 |
Not clear |
| Frank-Gerald Pajon. Risperidone in acute and long-term therapy of schizophrenia--a clinical profile. Progress in neuro-psychopharmacology & biological psychiatry. vol 28. issue 1. 2004-02-18. PMID:14687852. |
this review describes comprehensive trial data and therapeutic observations gained with risperidone in the treatment of schizophrenia since its approval. |
2004-02-18 |
2023-08-12 |
Not clear |
| Michael Philipp, Otto M Lesch, Max Schmauss, Matthias Dose, Thomas Glase. [Comparative effectiveness of flupenthixol and risperidone on negative symptoms of schizophrenia]. Psychiatrische Praxis. vol 30 Suppl 2. 2004-02-17. PMID:14509050. |
[comparative effectiveness of flupenthixol and risperidone on negative symptoms of schizophrenia]. |
2004-02-17 |
2023-08-12 |
Not clear |
| Peter D Feldman, Christopher J Kaiser, John S Kennedy, Virginia K Sutton, Pierre V Tran, Gary D Tollefson, Fan Zhang, Alan Breie. Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years. The Journal of clinical psychiatry. vol 64. issue 9. 2004-02-17. PMID:14628974. |
comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years. |
2004-02-17 |
2023-08-12 |
Not clear |
| Emmanuelle Levy, Howard C Margolese, Sarah Sultan, Guy Chouinar. Obsessive-compulsive symptoms in schizophrenia induced by risperidone and responding to fluoxetine. Canadian journal of psychiatry. Revue canadienne de psychiatrie. vol 48. issue 10. 2004-02-17. PMID:14674056. |
obsessive-compulsive symptoms in schizophrenia induced by risperidone and responding to fluoxetine. |
2004-02-17 |
2023-08-12 |
Not clear |
| Vicente Molina, Santiago Reig, Javier Pascau, Javier Sanz, Fernando Sarramea, Juan D Gispert, Rogelio Luque, Carlos Benito, Tomás Palomo, Manuel Desc. Anatomical and functional cerebral variables associated with basal symptoms but not risperidone response in minimally treated schizophrenia. Psychiatry research. vol 124. issue 3. 2004-01-29. PMID:14623068. |
anatomical and functional cerebral variables associated with basal symptoms but not risperidone response in minimally treated schizophrenia. |
2004-01-29 |
2023-08-12 |
human |
| Maria B Isaac, Michael T Isaa. Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 28. issue 11. 2004-01-28. PMID:12968130. |
effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. |
2004-01-28 |
2023-08-12 |
Not clear |
| W Wolfgang Fleischhacker, Mariëlle Eerdekens, Keith Karcher, Gary Remington, Pierre-Michel Llorca, Wlodzimierz Chrzanowski, Stephen Martin, Ola Gefver. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. The Journal of clinical psychiatry. vol 64. issue 10. 2004-01-21. PMID:14658976. |
treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. |
2004-01-21 |
2023-08-12 |
Not clear |
| W Wolfgang Fleischhacker, Mariëlle Eerdekens, Keith Karcher, Gary Remington, Pierre-Michel Llorca, Wlodzimierz Chrzanowski, Stephen Martin, Ola Gefver. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. The Journal of clinical psychiatry. vol 64. issue 10. 2004-01-21. PMID:14658976. |
the long-term safety and efficacy of long-acting injectable risperidone, the first long-acting second-generation antipsychotic, were evaluated in stable patients with schizophrenia. |
2004-01-21 |
2023-08-12 |
Not clear |
| Pierre Fortier, Jean-Pierre Mottard, Gilles Trudel, Sandrine Eve. Study of sexuality-related characteristics in young adults with schizophrenia treated with novel neuroleptics and in a comparison group of young adults. Schizophrenia bulletin. vol 29. issue 3. 2004-01-14. PMID:14609249. |
proportionally more men with schizophrenia treated with risperidone or olanzapine than men in the comparison group had at least one sexual dysfunction, lacked sexual desire, and reported problems with sexual arousal and ejaculation. |
2004-01-14 |
2023-08-12 |
Not clear |
| J Bobes, J Rejas, M Garcia-Garcia, F Rico-Villademoros, M P García-Portilla, I Fernández, G Hernánde. Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study. Schizophrenia research. vol 62. issue 1-2. 2004-01-08. PMID:12765747. |
weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the eire study. |
2004-01-08 |
2023-08-12 |
Not clear |